Abstract
Expression of CD44 and of specific splice-variants of CD44 has been causally related to metastatic behaviour in a variety of carcinomas and lymphomas. To elucidate whether, in principle, similar splice-variants could be involved in glioma cell invasion we examined the expression of CD44 and its splice-variants in a series of 38 primary human brain tumors (28 astrocytomas, WHO grade I-III and 10 glioblastomas, WHO grade IV) and in cell lines derived from 9 glioblastomas. All brain tumors examined showed strong immunoreactivity for an N-terminal epitope present on all CD44 isoforms known. Using a polyclonal antiserum raised against the complete sequence encoded by variant exons v3 to v10, CD44 splice-variants could be detected irrespective of the grade of malingnancy in many of the tumor samples at a low level and often restricted to only a few clustered tumor cells. Thus, the N-terminal epitope probably indicates the presence of the smallest and most ubiquitous isoform CD44s. Interestingly, all glioblastomas expressed CD44 variants whereas expression in astrocytomas WHO grade I, II, and III could only be detected in about half of the tumor samples.
Using reverse transcriptase-PCR we were able to detect different CD44 splice-variants in the glioblastoma cell lines and in cultured primary astrocytic cells. Glioblastoma cells analyzed by flow cytometry showed the expected binding capacity for hyaluronic acid which could be increased twofold after pretreatment with hyaluronidase.
The results presented show that there is low expression of CD44 variants in human tumors of astrocytic origin. Expression of CD44 and its splice-variants could contribute to the migration capacity of neoplastic astrocytes, and may be considered as a target for new diagnostic and therapeutic approaches in the clinical management of brain tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
He Q, Lesley J, Hyman R, Ishihara K, Kincade PW: Molecular isoforms of murine CD44 and evidence that the membrane proximal domain is not critical for hyaluronate recognition. J Cell Biol 119: 1711–1719, 1992
Herrlich P, Rudy P, Hofmann M, Arch R, Zöller M, Zawadzki V, Tölg C, Hekele A, Koopman G, Pals S, Heider K-H, Sleeman J, Ponta H: CD44 and splice variants of CD44 in normal differentiation and tumor progression. In: Hemler ME, Mihich E (eds) Cell Adhesion Molecules. Plenum Press, New York, London 265–288, 1993
Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160–12164, 1992
Tölg C, Hofmann M, Herrlich P, Ponta H: Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 21: 1225–1229, 1993
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303–1313, 1990
Turley EA, Austen L, Moore D, Hoare K: Ras-transformed cells express both CD44 and RHAMM hyaluronan receptors: only RHAMM is essential for hyaluronan-promoted locomotion. Exp Cell Res 207: 277–282, 1993
Sy MS, Guo Y-J, Stamenkovic I: Distinct effects of two CD44 isoforms on tumor growthin vivo. J Exp Med 174: 859–866, 1991
Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haűmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13–24, 1991
Sy M-S, Guo Y-J, Stamenkovic I: Inhibition of tumor growthin vivo with a soluble CD44-immunoglobulin fusion protein. J Exp Med 176: 623–627, 1992
Herrlich P, Zöller M, Pals ST, Ponta H: CD44 splice variants: Metastases meet lymphocytes. Immunol Today 14: 395–399, 1993
Sleeman J, Moll J, Sherman L, Dall P, Pals ST, Ponta H, Herrlich P: The role of CD44 splice variants in human metastatic cancer. Ciba Foundation Symposium, No. 189 on cell adhesion and human disease. J Wiley and Sons Ltd., Chichester, UK, 1994, (in press)
Girgrah N, Letarte M, Becker LE, Cruz TF, Theriault E, Moscarello MA: Localization of the CD44 glycoprotein to fibrous astrocytes in normal white matter and to reactive astrocytes in active lesions in multiple sclerosis. J Neuropathol Exp Neurol 50: 779–792, 1991
Moretto G, Xu RY, Kim SU: CD44 expression in human astrocytes and oligodendrocytes. J Neuropathol Exp Neurol 52: 419–423, 1993
Haegel H, Tölg C, Hofmann M, Ceredig R: Activated mouse astrocytes and T cells express similar CD44 variants. Role of CD44 in astrocyte/T cell binding. J Cell Biol 122: 1067–1077, 1993
Merzak A, Koocheckpour S, Pilkington GJ: CD44 mediates human glioma cell adhesion and invasion. Cancer Res 54: 3988–3992, 1994
Heider K-H, Hofmann M, Horst E, van den Berg F, Ponta H, Herrlich P, Pals ST: A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120: 227–233, 1993a
Li H, Hamou MF, de Tribolet N, Jaufeerally R, Hofmann M, Diserens AC, Van Meir EG: Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res 53: 5345–5349, 1993
Shtivelman E, Bishop M: Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 11: 5446–5453, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eibl, R.H., Pietsch, T., Moll, J. et al. Expression of variant CD44 epitopes in human astrocytic brain tumors. J Neuro-Oncol 26, 165–170 (1995). https://doi.org/10.1007/BF01052619
Issue Date:
DOI: https://doi.org/10.1007/BF01052619